As a result, this enhanced laminin binding to dystroglycan, suggesting the potential for ribitol to enhance muscle function in dystroglycanopathy patients with an FKRP mutation. This evidence concerns the gene FKRP and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.